Press coverage about Quotient (NASDAQ:QTNT) has been trending somewhat positive this week, according to Accern Sentiment. The research firm scores the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Quotient earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.1212163171721 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Shares of QTNT stock traded down $0.05 on Wednesday, reaching $5.70. The company had a trading volume of 169,719 shares, compared to its average volume of 477,970. The company has a debt-to-equity ratio of 22.54, a current ratio of 2.34 and a quick ratio of 1.65. Quotient has a 52-week low of $2.78 and a 52-week high of $7.74.
Quotient (NASDAQ:QTNT) last announced its quarterly earnings results on Monday, February 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.08. The firm had revenue of $5.86 million during the quarter, compared to the consensus estimate of $5.20 million. Quotient had a negative return on equity of 13,050.41% and a negative net margin of 342.23%. sell-side analysts predict that Quotient will post -2.07 EPS for the current fiscal year.
In other news, Director Brian Mcdonough acquired 10,000 shares of the firm’s stock in a transaction dated Thursday, February 8th. The stock was acquired at an average cost of $3.87 per share, with a total value of $38,700.00. Following the completion of the acquisition, the director now owns 47,747 shares of the company’s stock, valued at $184,780.89. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Prondzynski Heino Von acquired 12,000 shares of the firm’s stock in a transaction dated Wednesday, February 21st. The stock was purchased at an average cost of $4.28 per share, with a total value of $51,360.00. The disclosure for this purchase can be found here. Corporate insiders own 29.00% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Quotient (NASDAQ:QTNT) Given Daily News Sentiment Rating of 0.23” was originally posted by BBNS and is owned by of BBNS. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://baseballnewssource.com/2018/03/21/quotient-qtnt-earns-daily-media-impact-rating-of-0-23/2029198.html.
Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.